key: cord-1003113-5utq6bzk
authors: Merzon, Eugene; Green, Ilan; Vinker, Shlomo; Golan‐Cohen, Avivit; Gorohovski, Alessandro; Avramovich, Eva; Frenkel‐Morgenstern, Milana; Magen, Eli
title: The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID‐19 infection
date: 2021-02-23
journal: FEBS J
DOI: 10.1111/febs.15784
sha: af02d5847a7a1f4faf6d2dffb14242af52c6ec6c
doc_id: 1003113
cord_uid: 5utq6bzk

Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID‐19 susceptibility and disease duration. We conducted a retrospective population‐based cross‐sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID‐19‐positive group, as compared to the COVID‐19‐negative group (73 (11.03 %) vs. 1548 (15.77%); p=0.001). Aspirin use was associated with lower likelihood of COVID‐19 infection, as compared to non‐users (adjusted OR 0.71 (95% CI, 0.52 to 0.99; p=0.041). Aspirin users were older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; p<0.001), presented a lower BMI (28.77±5.4 vs. 30.37±4.55; p<0.0189) and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%) and COPD (11, 15.07%) than showed the aspirin non‐users (151, 25.64%, p<0.001; 130, 22.07%, p<0.001; and 43, 7.3%, p=0.023, respectively). Moreover, COVID‐19 disease duration (considered as the time between the first positive and second negative COVID‐19 RT‐PCR test results) among aspirin users was significantly shorter, as compared to aspirin non‐users (19.8±7.8 vs. 21.9± 7.9 p= 0.045). Among hospitalized COVID‐positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (p=0.449). In conclusion, we observed inverse association between the likelihood of COVID‐19 infection, disease duration and mortality and aspirin use for primary prevention.

Surveillance of the clinical characteristics of patients with coronavirus disease 2019 is important for clarifying the epidemiology of the disease. Several epidemiological studies have suggested that individuals with diabetes, cardiovascular disease (CVD), or chronic lung disease are at higher risk for COVID-19 infection (1, 2) . While many reports on COVID-19 have emphasized age-, sex-and comorbid disease-

This article is protected by copyright. All rights reserved related differences in health outcomes, pharmacological treatment differences in infection susceptibility have yet to be described in-depth.

Acetylsalicylic acid (aspirin) is among the most used medications in the world for the treatment of acute coronary syndromes and secondary prevention of CVD (3) . Recent trials have, however, revealed that low-dose aspirin is not associated with significant differences in terms of primary CVD prevention (4, 5) . Therefore, the American College of Cardiology and the American Heart Association, who previously published guidelines for aspirin use in primary prevention, now discourage routine use of aspirin, particularly in patients with increased risk of bleeding (6) . Nevertheless, many individuals still receive low-dose aspirin for primary prevention (7) . Aspirin has multiple effects on different components of innate and adaptive immunity and, therefore, can influence susceptibility to viral infections (8) . As such, we hypothesized that pre-existing treatment with low-dose aspirin might have a protective effect on COVID-19 susceptibility and disease duration among COVID-19-infected subjects. We accordingly analyzed the prevalence of lowdose aspirin therapy and clinical characteristics of that group in a large cohort of consecutive outpatients who tested positive in an RT-PCR assay designed to detect infection with COVID-19.

We directed a retrospective population-based cross-sectional study utilizing data from the Leumit Health Services (LHS) database. LHS is a nation-wide health maintenance organization in Israel, which provides services to some 725,000 members. LHS maintains a wide-ranging computerized database, continuously updated in terms of member hospitalizations and laboratory tests, demographics, medical diagnoses, and medical encounters. During each physician visit, the patient's diagnosis is entered or updated according to the International Classification of Diseases (9 th revision, ICD-9). At the same time, there is an ongoing process of validation by which the physicians are encouraged to report on patients, their diagnosis classification, medications and services. As such, the validity of diagnoses entered into the registry is high for important medical diagnoses, in particular those based on the LHS laboratory data (9) (10) (11) (12) .

This article is protected by copyright. All rights reserved

The study period was from February 1, 2020 to June 30, 2020. The first COVID-19 patient in Israel was diagnosed in February 2020 and on July 9, the criteria used for defining recovery from COVID-19 were changed (13 

Data on demographics, laboratory results, and ICD-9 codes were derived from the LHS electronic medical records (EMR) system. COVID-19 RT-PCR testing of samples derived from nasopharyngeal swabs was performed by experienced personnel in a single centralized laboratory accordingly to international guidelines (14). All consecutive patients aged ≥40 years who had been tested for COVID-19 during the study period were included in the study. The EMR of each subject was reviewed and those patients receiving low-dose aspirin treatment 4 weeks prior to COVID-19 RT-PCR testing were identified. Individuals who had been diagnosed with coronary artery disease, cerebrovascular disease and/or peripheral vascular disease were classified as taking aspirin for secondary prevention and excluded from the study. Such exclusion was performed to reduce the risk of bias due to differences in social activity and hence differences in potential COVID-19 exposure between healthy and more socially active populations and those patients suffering from cardiovascular diseases and accordingly, less socially active.

This article is protected by copyright. All rights reserved

A total of 10,477 subjects were identified who had been tested for COVID-19 by RT-PCR and who had received and purchased at least 3 prescriptions for aspirin for primary prevention. Comparison of various demographic and clinical characteristics in these subjects, both positive and negative for COVID-19, are presented in Table 1 (Table 1) . Moreover, there were no differences between COVID-19positive and COVID-19-negative subjects in terms of the proportion of patients treated with ACE inhibitors (65 (9.82 %) vs.1162 (11.86 %)) and angiotensin II receptor blockers (ARBs) (28(4.23 %) vs. 540 (5.51 %))( Table 1) .

Demographic and clinical characteristics of COVID-19-positive subjects receiving aspirin treatment (aspirin users) vs. COVID-19-positive subjects not receiving aspirin treatment (aspirin non-users) are presented in Table 2 

This article is protected by copyright. All rights reserved diabetes (47(64.38%)) and COPD (11 (15.07 %)) versus aspirin non-users (151 (25.64%), p<0.001; 130 (22.07%), p<0.001; and 43 (7.3%), p=0.023, respectively).

Moreover, among aspirin users, a significantly higher proportion of subjects were treated with ACE inhibitors (25 (34.25 %)), ARBs (10 (13.70 %)) and statins (52 (71.23 %)), relative to aspirin non-users (40 (6.79 %), p<0.001; 18 (3.06 %), p<0.001; and 56 (9.51 %), p<0.001, respectively). The variance inflation factor (VIF) was used to account for the problem of multi-collinearity among independent variables used. All VIFs were less than 5, indicative of a degree of multi-collinearity in our data, although one not sufficiently severe to warrant further corrective measures (see Table 1 and Figure 1 ).

Demographic and clinical characteristics of hospital-treated COVID-19-positive patients (n= 112) vs. community-treated COVID-19-positive patients (n= 550) are presented in Table 3 . Hospitalized patients were significantly older (62.89±12.19 vs. 56.91±12.19 years of age; p<0.001) and showed higher prevalence of hypertension (46 (41.07%)), diabetes (47 (41.96%)) and COPD (15 (13.39)) than did community-treated patients (161 (29.27)), p=0.014; (130 (22.07%)), p<0.001; and (39 (7.09)), p=0.026, respectively).

Hospitalized patients also had significantly higher hemoglobin A1C levels than did community-treated patients (6.26%±1.85 and 5.70%±1.4, p=0.002, respectively). Older age and higher ages of comorbidities were noted among hospital-treated patients, as compared to community-treated patients. This may be explained by the significantly higher proportion of subjects treated with aspirin (21 (18.75%) versus 51 (9.27%), p= 0.003). After adjustment for age, sex and comorbidities, this difference disappeared (adjusted OR 1.00 (95% CI, 0.47-2.57; p=0.826)) ( Table 3) .

Seven subjects of the 112 hospitalized COVID-19-positive patients died during the study period. Their demographic and clinical characteristics are presented in Table 4 .

Dead subjects were significantly older (80.71±20.51 vs. 61.72±13.50 years of age; p<0.0007). After adjustment for other variables, only age, as a continuous variable, appeared to be a significant risk factor for mortality, introducing an additional 9% for every year (adjusted OR 1.09 (95% CI, 1.02-1.17; p=0.009)) ( Table 4 ). Among surviving hospitalized patients, a higher proportion of subjects were treated with aspirin (20 (19.05%) vs. 1 (14.29%), adjusted OR 0.36 (95% CI, 0.02-6.85)) and statins (23 (21.90) 

This article is protected by copyright. All rights reserved vs. 1 (14.29), OR 0.31 (95% CI, 0.01-6.57)), although this difference was not significant (p=0.449 and p= 0.514, respectively) ( Table 4) .

To strengthen the hypothesis that aspirin pharmacotherapy for primary prevention has a possible protective effect against COVID-19 infection, a separate analysis of the conversion time of a SARS-CoV-2 RT PCR test result from positive to negative among COVID-19-positive subjects was performed. Demographic and clinical characteristics of COVID-19-positive patients with and without aspirin treatment are presented in Table 2 .

The time between the first positive SARS-CoV-2 RT-PCR test result and the first and second negative SARS-CoV-2 RT-PCR test results among aspirin users was significantly shorter, as compared to that time measured for aspirin non-users ((15.66±7.15 vs.

18.38± 7.71 days p= 0.0052) and (19.81±7.77vs. 21.91± 7.88 p= 0.045), respectively) ( Table 2 ). Figure 2 presents the effect of aspirin on conversion time among COVID-19positive patients, using a statistical R function Welch two-sample t-test. This means that a significant difference exists in all tests, with a significance threshold of p-value<0.05.

These results indicate a reduction in the duration of illness by an average of about 1.2 times in the case of those taking aspirin.

A large, nation-wide study revealed that the use of aspirin is associated with a decreased likelihood of a positive COVID-19 test result. Indeed, aspirin gained remarkable popularity during the 1918 Spanish Influenza pandemic, several decades prior to confirmation of its action on several components of innate immunity (8) and the in vitro efficacy against RNA viruses of the respiratory tract (18) . The basic mechanism of the anti-viral activity of aspirin against RNA viruses relies on several biochemical and immunological pathways.

Host response and clearance of viral infections heavily depend on the expression of type I interferon (IFN), which modulates cell responses and reprograms cells into an "anti-viral state" (19) . RNA viruses, such as SARS-CoV and MERS-CoV, can escape immune system recognition via suppression of type I IFN signaling through an inhibition of STAT

This article is protected by copyright. All rights reserved family transcription factor phosphorylation (20) . Another specific mechanism used by RNA viruses to evade host anti-viral responses involves up-regulation of prostaglandin E 2 (PGE 2 ) levels, which leads to an inhibition of type I IFN production and apoptosis in macrophages, thereby causing increased viral replication (21) . As low-dose aspirin inhibits PGE 2 biosynthesis (22) , this mechanism might enhance anti-viral immunity via induction of type I INF (23) .

COVID-19 uses the transmembrane angiotensin-converting enzyme 2 (ACE2) as the host transmembrane cellular receptor for cell infection (24) . Higher ACE2 expression may be of benefit in preventing COVID-19 infection, as COVID-19 virus particles may compete with angiotensin-2 protein for cell surface binding sites and cellular uptake (25) .

In addition, the stimulator of interferon genes (STING) induces type I INF production when cells are infected with DNA and RNA viruses (26) . Furthermore, polymorphisms in the STING pathway contribute to the pathogenesis of COVID-19 infection (27) .

Interestingly, aspirin has been found to directly affect an acetylate cyclic GMP-AMP synthase (cGAS) that activates a type I INF response via the STING pathway (29) . In COVID-19, excessive angiotensin II signaling due to poor ACE2-mediated conversion of angiotensin II at the cell surface could activate the STING pathway (30) . Accordingly, Chow et al. suggested that COVID severity would be reduced among aspirin users. In their recent retrospective on an observational cohort study of adult patients admitted with COVID-19 to multiple hospitals in the United States, these authors found that aspirin use was associated with decreased rates of mechanical ventilation, ICU admission, and inhospital mortality (28) . 

This article is protected by copyright. All rights reserved

The present study, to our knowledge, is the first to examine the relationship between low-dose aspirin treatment and the likelihood of COVID-19 infection among a large cohort of outpatients listed in a nation-wide database. In addition, we found a reduction in COVID19 likelihood for individuals using both aspirin and statins (Figure 3) .

A major limitation in our observational study is the lack of control over treatments given to the study population. Unlike random assignment in clinical trials, where groups differ only in terms of treatment intervention, the treatment groups in observational studies, such as the present study, are likely to differ with respect to treatment intervention and other variables that can independently affect outcome. To avoid bias due to comparison of a healthy, more socially active population with patients suffering from severe cardiovascular comorbidity, we excluded all subjects taking aspirin for secondary prevention. We also applied multivariate logistic regression analysis adjusted for sex, age, smoking status, socioeconomic status (SES), chronic medication administration, laboratory data and comorbidities and used the variance inflation factor (VIF) (17) to check for multi-collinearity among independent variables. Another serious limitation is related to the observed shortening of PCR positivity among aspirin users, given how PCR testing was not performed on a daily basis in the community setting. However, two consecutive negative SARS-CoV-2 RT-PCR test results were recommended as a criterion for discharge and termination of social isolation by health authorities in different countries and were used for making a clinical decision regarding COVID-19 management 

This article is protected by copyright. All rights reserved

In conclusion, we observed inverse association between the likelihood of COVID-19 infection and aspirin use for primary prevention. Our data on the possible use of lowdoses of aspirin for the prevention of COVID-19 infection are preliminary, yet intriguing.

We thus need prompt clinical consideration of this safe, low-cost drug with the potential to favorably alter COVID-19 infection outcome. Such an effect would also provide immediate socio-economical relief by reduction of COVID-19 susceptibility. Therefore, our observations justify efforts to repeat this study using larger samples, including patients from other institutions.

This article is protected by copyright. All rights reserved

Medication use was deemed if the patient had been prescribed and had purchased at 

This article is protected by copyright. All rights reserved

Fisher's exact χ2 test for continuous and categorical variables, respectively, based on normal distribution and variable characteristics. Categorical data are presented as counts and percentages. Data on continuous variables with normal distribution are presented as means and standard deviation (SD). We applied multiple imputations for missing data under the assumption that data were missing at random, conditional on the observed data. Any problem of multi-collinearity among variables in the models was tested by calculating the VIF (17) . Multiple regression analyses adjusted for sex, age, smoking status, comorbidity and chronic medication use served to estimate the odds ratios (OR) and 95% confidence interval (CI) for the independent association between aspirin treatment and COVID-19 RT-PCR test results. All statistical analyses were conducted 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

The aspirin story -from willow to wonder drug

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Role of aspirin in primary prevention of cardiovascular disease

Aspirin and immune system

Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer

Prevalence of selected chronic diseases in Israel

The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization

Accepted Article This article is protected by copyright. All rights reserved

The epidemiology of diabetes in a large Israeli HMO

World Health Organization (WHO), Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim guidance

Multicollinearity and misleading statistical results

Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study. Influenza Other Respir Viruses

Shared and Distinct Functions of Type I and Type III Interferons

SARS and MERS: recent insights into emerging coronaviruses

Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages

Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis

Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages

A new coronavirus associated with human respiratory disease in China

Accepted Article This article is protected by copyright. All rights reserved

Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)

STING-ing the antiviral pathway

COVID-19 as a STING disorder with delayed over-secretion of interferon-beta

Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19

Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?

A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance

Platelet gene expression and function in patients with COVID-19

Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19

Proteomic and Metabolomic Characterization of COVID-19

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

/m 2 (mean ± SD) 30

Diabetes mellitus, n (%) 4 (57.14%)

We thank the Leumith Health System for providing all the ethical applications for this study. MFM is supported by the Israel Innovation Authority (Kamin grant #66824, 2019-2020) and COVID-19 Data Science Institute (DSI) grant, Bar-Ilan University (#247017, 2020).

This article is protected by copyright. All rights reserved